ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026
No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeWe evaluated the reach, treatment selection, and effectiveness of a population-based, opt-out smoking cessation outreach program, No Smoker Left Behind, implemented in a socioeconomically and racially diverse cancer patient population.
methodsPatients seeking oncology care at the University of Chicago Comprehensive Cancer Center between 2019 and 2024 were screened for smoking status as documented in the electronic health record. Adults age 18 years and older categorized as currently smoking (past month) were systematically contacted via interactive voice response phone calls, texts, and emails for up to 6 months. They were offered several cessation treatment options, including medication and counseling referrals (ie, group program, quitline, and text message program). Program involvement and cessation outcomes were compared by cancer type (ie, smoking- or non-smoking-related) and race. A cost-outcome analysis was also conducted.
resultsOf 37,478 patients with cancer, 3,706 (9.9%) were deemed eligible and contacted, of whom 57.0% were male, 46.6% Black, and 63.8% publicly insured. Of those selecting cessation treatments (n = 1,089), most self-selected both medication and counseling (70.6%), with 873 receiving referrals or connection to cessation support. Among patients who completed day 180 follow-up (37.5% of those receiving referrals), 16.2% (53/327) self-reported ≥8-day abstinence. Patients with smoking-related cancers had higher abstinence rates than patients with non-smoking-related cancers (23.7%
conclusionPopulation-based, proactive opt-out outreach programs provide a feasible approach for offering multiple cessation treatment options that allow for patient preference and customization to optimize treatment accessibility. As health care systems expand access to tobacco cessation as part of cancer care, implementing resource-efficient models will become increasingly important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.